New York State Teachers Retirement System Has $16.29 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

New York State Teachers Retirement System trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,681 shares of the company’s stock after selling 927 shares during the period. New York State Teachers Retirement System owned approximately 0.11% of Medpace worth $16,289,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. NewEdge Advisors LLC boosted its stake in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Voya Investment Management LLC boosted its position in shares of Medpace by 7.6% during the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company’s stock valued at $6,696,000 after buying an additional 1,560 shares during the last quarter. Finally, Lifestyle Asset Management Inc. grew its holdings in Medpace by 10.2% during the second quarter. Lifestyle Asset Management Inc. now owns 4,624 shares of the company’s stock worth $1,451,000 after buying an additional 427 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In related news, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 387,925 shares of company stock worth $233,386,647 in the last 90 days. 20.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on MEDP. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Robert W. Baird set a $613.00 price objective on shares of Medpace in a research note on Friday, October 24th. Mizuho set a $660.00 target price on Medpace in a research note on Friday. Finally, BMO Capital Markets assumed coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $491.27.

Medpace Trading Up 1.5%

MEDP opened at $608.43 on Wednesday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26. The company has a market cap of $17.14 billion, a PE ratio of 42.55, a price-to-earnings-growth ratio of 2.01 and a beta of 1.43. The company has a 50 day moving average of $581.43 and a 200 day moving average of $506.43.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.